The small molecule IDH2 inhibitor enasidenib, active against IDH2 R140 and IDH2 R172 variants [41], was approved by the FDA in 2017 for relapsed/refractory IDH2-mutated AML [48], with the advantage of its efficacy in certain types of acute myeloid leukemia (AML) against reduced white blood cells or relapse, even after the treatment with previously approved chemotherapy medications. This evidence concerns the gene IDH2 and acute myeloid leukemia.